Dana-Farber News

Latest Articles

• Dana-Farber Debuts 50 Clinical Studies on Pancreatic Cancer and AI Diagnostics at AACR 2026

  Published: Apr 18, 2026

  Section: Research

  Researchers from the Dana-Farber Cancer Institute are presenting over 50 scientific studies at the 2026 American Association for Cancer Research Annual Meeting. Key highlights incl...

• Genetically Engineered Virus Therapy Successfully Activates Immune System to Combat Aggressive Glioblastoma Brain Tumors

  Published: Mar 20, 2026

  Section: Medical News

  Researchers from Mass General Brigham and Dana-Farber have demonstrated that a modified herpes virus can effectively infiltrate "cold" brain tumors to trigger a robust immune respo...

• Alliance for Clinical Trials Launches Phase III Study Integrating Targeted Therapy for Grade 3 Astrocytoma

  Published: Mar 16, 2026

  Section: Science & Tech

  A new clinical trial (Alliance A072301) is investigating whether combining the targeted drug vorasidenib with standard chemotherapy after radiation improves survival for patients w...

• Phase 3 LITESPARK 022 study establishes new oral combination therapy for preventing kidney cancer recurrence after surgery

  Published: Mar 2, 2026

  Section: Health Technology

  A global clinical trial has demonstrated that combining the HIF 2α inhibitor belzutifan with standard immunotherapy significantly reduces the risk of relapse in patients with clear...

• Phase 3 trial shows belzutifan and pembrolizumab combination reduces kidney cancer recurrence risk after surgery

  Published: Mar 2, 2026

  Section: Health

  Patients with clear cell renal cell carcinoma at high risk of relapse demonstrated improved disease free survival when treated with a combination of belzutifan and pembrolizumab. D...